Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis

Two HER2-specific mAbs, trastuzumab and pertuzumab (T+P), combined with chemotherapy comprise standard-of-care treatment for advanced HER2+ breast cancers (BC). While this antibody combination is highly effective, its synergistic mechanism-of-action (MOA) remains incompletely understood. Past studie...

Full description

Saved in:

Bibliographic Details
Published in:	JCI insight Vol. 7; no. 6
Main Authors:	Tsao, Li-Chung, Crosby, Erika J, Trotter, Timothy N, Wei, Junping, Wang, Tao, Yang, Xiao, Summers, Amanda N, Lei, Gangjun, Rabiola, Christopher A, Chodosh, Lewis A, Muller, William J, Lyerly, Herbert Kim, Hartman, Zachary C
Format:	Journal Article
Language:	English
Published:	United States American Society for Clinical Investigation 22-03-2022 American Society for Clinical investigation
Subjects:	Animals Antibodies, Monoclonal, Humanized Breast Neoplasms - pathology Cell Line, Tumor Complement C1q Female Humans Mice Oncology Phagocytosis Receptor, ErbB-2 - metabolism Therapeutics Trastuzumab - pharmacology Trastuzumab - therapeutic use Oncology Complement Cancer immunotherapy Therapeutics
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!